updated analysis of the observational GioTag study
Maximilian J Hochmair (Avtor), Alessandro Morabito (Avtor), Desiree Hao (Avtor), Cheng-Ta Yang (Avtor), Ross A Soo (Avtor), James C-H Yang (Avtor), Rasim Gucalp (Avtor), Balazs Halmos (Avtor), Lara Wang (Avtor), Angela Märten (Avtor), Tanja Čufer (Avtor)

Povzetek

Aims: Overall survival (OS) and updated time to treatment failure (TTF) analysis of patients with EGFR mutation-positive (Del19, L858R) non-small-cell lung cancer who received sequential afatinib/osimertinib in the real-world GioTag study. Patients & methods: Patients had T790M-positive disease following first-line afatinib and received osimertinib treatment (n = 203). Primary outcome was TTF. The OS analysis was exploratory. Results: Median OS was 41.3 months (90% CI: 36.8-46.3) overall and 45.7 months (90% CI: 45.3-51.5) in patients with Del19-positive tumors (n = 149); 2-year survival was 80 and 82%, respectively. Updated median TTF with afatinib and osimertinib was 28.1 months (90% CI: 26.8-30.3). Conclusion: Sequential afatinib/osimertinib was associated with encouraging OS/TTF in patients with EGFR T790M-positive non-small-cell lung cancer, especially in patients with Del19-positive tumors.

Ključne besede

osimertinib;raziskava GioTag;GioTag study;

Podatki

Jezik: Angleški jezik
Leto izida:
Tipologija: 1.01 - Izvirni znanstveni članek
Založnik: Future Medicine Ltd
UDK: 616.2
COBISS: 2048610929 Povezava se bo odprla v novem oknu
ISSN: 1744-8301
Št. ogledov: 917
Št. prenosov: 559
Ocena: 0 (0 glasov)
Metapodatki: JSON JSON-RDF JSON-LD TURTLE N-TRIPLES XML RDFA MICRODATA DC-XML DC-RDF RDF

Ostali podatki

Sekundarne ključne besede: Carcinoma, non-small cell lung;Therapy;Drug therapy;Afatinib;Nedrobnocelični karcinom pljuč;Terapija;Terapija z zdravili;
Komentar vira: Nasl. z nasl. zaslona; Soavtorica iz Slovenije: Tanja Cufer; Opis vira z dne 10. 1. 2020;
Strani: str. 2905-2914
Letnik: ǂVol. ǂ15
Zvezek: ǂiss. ǂ25
Čas izdaje: Sep. 2019
DOI: 10.2217/fon-2019-0346
ID: 12014831